Vor Biopharma (NASDAQ:VOR) Research Coverage Started at TD Cowen

TD Cowen initiated coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research report report published on Wednesday, Marketbeat.com reports. The brokerage issued a buy rating on the stock.

Several other equities research analysts also recently weighed in on VOR. Robert W. Baird upgraded Vor Biopharma from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $20.00 to $64.00 in a report on Wednesday, October 15th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, September 24th. Wedbush began coverage on shares of Vor Biopharma in a report on Tuesday, November 25th. They issued a “neutral” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Vor Biopharma in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $43.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Vor Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $68.43.

Vor Biopharma Trading Down 3.0%

NASDAQ:VOR opened at $12.41 on Wednesday. Vor Biopharma has a 52 week low of $2.62 and a 52 week high of $65.80. The stock has a fifty day simple moving average of $16.49. The firm has a market capitalization of $129.19 million, a P/E ratio of -0.03 and a beta of 2.08.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 260,859 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $29.39, for a total value of $7,666,646.01. Following the completion of the sale, the director owned 15,104 shares in the company, valued at $443,906.56. This represents a 94.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Reprogrammed Interchange Llc sold 75,262 shares of the stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $33.87, for a total transaction of $2,549,123.94. Following the sale, the insider owned 1,423,659 shares of the company’s stock, valued at approximately $48,219,330.33. This represents a 5.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,674,800 shares of company stock worth $49,516,960 over the last ninety days. Corporate insiders own 0.45% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Squarepoint Ops LLC acquired a new stake in Vor Biopharma in the third quarter valued at about $230,000. Bank of America Corp DE lifted its holdings in shares of Vor Biopharma by 679.3% in the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after buying an additional 4,144 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Vor Biopharma by 497.3% in the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after buying an additional 5,058 shares in the last quarter. Bridgeway Capital Management LLC acquired a new position in Vor Biopharma during the third quarter worth $304,000. Finally, Polymer Capital Management HK LTD purchased a new position in Vor Biopharma in the third quarter worth $1,035,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).